GL1X · GenesisL1 explorer

Research workbench

Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors

Analyse Structure-based discovery of novel amide-containing nicotinamide… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
4KFO
Type
protein
Length
942 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Nicotinamide phosphoribosyltransferase
EC
2.4.2.12
UniProt
P43490
Ligands
1QS, PO4
Pockets
7 · best druggability 0.80

Structure

x-ray diffraction · 2 distinct chains · 41% helix, 19% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ANicotinamide phosphoribosyltransferase (EC 2.4.2.12)protein47241% helix, 19% strandP43490
BNicotinamide phosphoribosyltransferase (EC 2.4.2.12)protein47040% helix, 19% strandP43490

Ligands and binding sites

  • 1QS · N-{4-[(3,5-difluorophenyl)sulfonyl]benzyl}imidazo[1,2-a]pyridine-6-carboxamide · ligand · 2 copies · chains A, B
  • PO4 · Phosphate ion · ion · 4 copies · chains A, B
  • EDO · 1,2-ethanediol · additive · 10 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

7 pockets found on a 1 Å grid, 3 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
17860.800.8382PO4, EDO, 1QS
27880.800.83831QS, PO4, EDO
36980.740.8060empty
4650.370.7923empty
5820.360.7614empty

Interfaces

1 interface between chains.

  • A–B · 4299 Ų buried · 78 hydrogen bonds · protein-protein

Compared structures

  • 4KFO · Structure-Based Discovery of Novel Amide-Containing Nicotinamide… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.